Skip to content

RF Applications for Residual LAA Leaks

Radiofrequency Energy Applications Targeting Significant Residual Leaks After Left Atrial Appendage Occlusion

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04726943
Acronym
REACT
Enrollment
100
Registered
2021-01-27
Start date
2021-02-01
Completion date
2022-12-31
Last updated
2021-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Left Atrial Appendage Thrombosis, Stroke, Ischemic

Keywords

stroke, atrial fibrillation, left atrial appendage, prevention, leak, radiofrequency

Brief summary

Although the clinical impact of residual left atrial appendage (LAA) leaks still requires confirmation, its patency resulting from incomplete LAA closure may promote blood stagnation and thrombus formation, and increase the risk of thromboembolic events. The main purpose of this trial is to evaluate the safety and efficacy of percutaneous leak closure with radiofrequency energy applications.

Detailed description

Therapies locally targeting the LAA via occlusion, exclusion, or excision have emerged as an alternative and effective approach for stroke prophylaxis in AF patients, especially those with OAC contra-indications. Despite mounting evidence of their safety and efficacy in comparison with standard oral therapy, device-related thrombus and incomplete LAA closure resulting in residual, significant leak may occur, potentially hindering an effective stroke prevention. Radiofrequency energy has been adopted in several settings (e.g., vascular, orthopedic, aesthetic surgery) to achieve thermal-induced tissue retraction.

Interventions

PROCEDURERadiofrequency Energy Applications

RF energy applications to the atrial edge of a leak resulting from incomplete LAA occlusion

Sponsors

Texas Cardiac Arrhythmia Research Foundation
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age\> 18 years. 2. Presence of a significant LAA leak acutely or at follow-up. 3. Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study

Exclusion criteria

1. Life expectancy \< 2 years. 2. pregnant, breastfeeding, or unwilling to practice birth control during participation in the study 3. presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

Design outcomes

Primary

MeasureTime frameDescription
Procedural Success1-3 monthsComplete LAA occlusion or presence of a mild/minimal peri-device leak on FU TEE

Secondary

MeasureTime frameDescription
Peri-Procedural SuccessPeri-ProceduralComplete LAA occlusion or presence of mild/minimal (1-2 mm) residual leak assessed via multiplane color Doppler imaging on TEE/ICE at the end of the procedure

Countries

United States

Contacts

Primary ContactAndrea Natale, MD
dr.natale@gmail.com512 544 8186
Backup ContactDomenico G Della Rocca, MD
domenicodellarocca@hotmail.it512 544 8186

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026